All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Business Development & Partnerships

WuXi Biologics, Qatar Free Zones Authority sign MoU to establish first Middle East CRDMO center
Manufacturing agreement, antibody, biologics, CRDMO services - Read more

THE GOOD
Clinical Trials

Vandria reports positive Ph1 results for VNA-318 in Alzheimer's disease, showing safety and target engagement
Small molecule, neurological, Alzheimer disease, dual mode of action, brain penetrant - Read more

Roche's trontinemab shows 92% amyloid clearance in Ph1/Ph2 trial for Alzheimer's disease
Antibody, neurological, monoclonal antibody, Alzheimer disease, amyloid-beta target, blood-brain barrier - Read more

Imvax seeks FDA meeting for IGV-001 personalized immunotherapy after Ph2 glioblastoma survival benefit despite endpoint miss
Antisense oligonucleotide, cancer, glioblastoma, personalized immunotherapy - Read more

Enterome's EO2401 OncoMimics immunotherapy shows survival benefit in Ph2 glioblastoma trial with nivolumab combination
Peptide therapy, cancer, OncoMimics peptides, glioblastoma, combination therapy, checkpoint inhibitor - Read more

Fractyl Health's Revita shows sustained weight maintenance post-GLP-1 discontinuation in Ph2 REVEAL-1 obesity study
Medical device, metabolic, endoscopic procedure, obesity, GLP-1 therapy, weight maintenance - Read more

Jasper Therapeutics reports positive Ph1b data for briquilimab targeting KIT in allergic asthma patients
Antibody, respiratory disease, monoclonal antibody, allergic asthma, KIT receptor, mast cell targeting - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Company Launches

ARCH, Parker Institute launch Medici Therapeutics, acquiring Nutcracker's $200M RNA programs
RNA therapeutics, oncology, strategic, major transaction - Read more [Paywall]

THE GOOD
Fundraises

Axoltis Pharma raises €18M ($20.9M) Series A, developing ALS drug candidate NX210c
Neurological, ALS, clinical-stage, blood-brain barrier - Read more

Metri Bio raises $5M Pre-Seed, developing therapeutics for endometriosis diseases
Women's health, platform technology, endometriosis, preclinical - Read more

HotHouse Therapeutics raises £2.9M ($3.83M) Pre-Seed, AI-powered plant bioengineering drug discovery platform
AI/ML platform, drug discovery, plant bioengineering, platform technology - Read more

THE GOOD
Market Reports

Pharma companies pledge $370B in US investments over five years amid Trump tariff policies
Manufacturing, strategic, major transaction, operational - Read more

THE GOOD
Politics & Policy

Bipartisan lawmakers introduce bill creating US biopharma manufacturing center to reduce foreign dependence
Biopharmaceuticals, strategic, regulatory, operational - Read more

THE GOOD
Regulatory

House unanimously passes bill to revive FDA's expired rare pediatric disease priority review voucher program
Rare disease, pediatric, regulatory, strategic, financial incentives - Read more

FDA proposes scaling back primate testing for antibody drugs using alternative safety assessment methods
Monoclonal antibody, regulatory, operational, cost reduction - Read more

THE GOOD
Strategic Plans

Tiziana spins out IL-6 drug TZLS-501 into separate public company citing Big Pharma interest
Monoclonal antibody, autoimmune, strategic, major transaction - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Janux reports mixed Ph1 data for JANX007 PSMA x CD3 T-cell engager in castration-resistant prostate cancer
T-cell engager, cancer, bispecific antibody, prostate cancer, PSMA target - Read more

Helicore suspends Ph1 trial of HCR-188 GIP antagonist for obesity, shifts focus to preclinical incretin conjugates
Monoclonal antibody, metabolic, GIP antagonist, obesity, incretin pathway - Read more

THE BAD
Regulatory

CDC vaccine panel to review childhood immunization schedule under new chair who opposes COVID vaccines
Vaccine, infectious disease, regulatory, operational - Read more

THE BAD
Strategic Plans

Pfizer discontinues Phase 1 ulcerative colitis drug PF-07899895 citing business priorities, not safety concerns
Small molecule, autoimmune, strategic, operational - Read more

THE UGLY
Regulatory

FDA's Richard Pazdur retires just three weeks after becoming CDER director, creating regulatory uncertainty
Regulatory, strategic, operational, leadership transition - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here